四环医药(00460.HK)与旺实生物就新冠治疗药物生产供应达成合作协议
四环医药(00460.HK)公布,旗下子公司吉林四环与旺实生物就口服核(甘)类抗新冠1类创新药氢溴酸氘瑞米德韦片VV116的生产供应达成合作协议。双方将密切配合推进VV116在技术转移、委托生产相关工作。
VV116为君实生物(01877.HK)下属控股子公司旺实生物申报的1类创新药氢溴酸氘瑞米德韦片,并于上月经国家药监局应急审评审批,附条件批准上市,该药被批准用于治疗轻中度新冠的成年患者。
根据双方协议约定及相关药品管理法规,吉林四环将作为受托生产方配合旺实生物开展产品的工艺优化、质量方法转移、中试放大、工艺验证等技术转移落产及委托生产注册审批工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.